EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

EGFR 阻断可逆转结直肠癌对 KRASG12C 抑制的耐药性

阅读：9

作者：Vito Amodio #, Rona Yaeger #, Pamela Arcella #, Carlotta Cancelliere, Simona Lamba, Annalisa Lorenzato, Sabrina Arena, Monica Montone, Benedetta Mussolin, Yu Bian, Adele Whaley, Marika Pinnelli, Yonina R Murciano-Goroff, Efsevia Vakiani, Nicola Valeri, Wei-Li Liao, Anuja Bhalkikar, Sheeno Thyparambi

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2020

起止号：

2020 Aug;10(8):1129-1139.

doi：

10.1158/2159-8290.CD-20-0187

研究方向：

肿瘤

疾病类型：

肠癌

Significance

The efficacy of KRASG12C inhibitors in NSCLC and colorectal cancer is lineage-specific. RTK dependency and signaling rebound kinetics are responsible for sensitivity or resistance to KRASG12C inhibition in colorectal cancer. EGFR and KRASG12C should be concomitantly inhibited to overcome resistance to KRASG12C blockade in colorectal tumors.See related commentary by Koleilat and Kwong, p. 1094.This article is highlighted in the In This Issue feature, p. 1079.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。